Lactoferrin in the reduction of circulating cholesterol,...

Details Lactoferrin in the reduction of circulating cholesterol,... Lactoferrin in the reduction of circulating cholesterol,...

2006-04-11

2006-04-11

Kerr, Kathleen M. (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C514S021800, C530S350000, C530S300000, C435S007100

Reexamination Certificate

active

07026295

ABSTRACT:
The present invention relates to methods of using lactoferrin (LF) to reduce circulating levels of cholesterol and vascular inflammation, in order to treat, prevent or reduce the incidence of atherosclerosis and cardiovascular disease.

REFERENCES:
patent: 6333311 (2001-12-01), Nuijens et al.
patent: 2002/0119928 (2002-08-01), McAnalley
patent: 2003/0060425 (2003-03-01), Ahlem et al.
patent: WO-0241912 (2002-05-01), None
Cianflone et al., Atherosclerosis, vol. 120, 1996, pp. 101-114.
Kajikawa et al, “Lactoferrin inhibits Cholestrol Accumulation in Macrophages Mediated by Acetylated or Oxidized Low-Density Lipoproteins,” Biochim Biophys Acta. Jun. 23, 1994; 1213(1): 82-90.
Croy et al, “All three LDL Receptor Homology Regions of the LDL Receptor-related Protein Binf Multiple Ligands,” Biochemistry Nov. 11, 2003; 42(44): 13049-13057.
Huettinger, M. et al, “The LDL-receptor Family: Lactoferrin and Lipid Metabolism,” Adv Exp. Med Biol. 1998; 443: 107-11.
Huettinger, m. et al, “Characteristics of Chylomicron Remnant Uptake into Rat Liver,” Clin Biochem. Apr. 1988; 21(2): 87-92.
van Dijk MC et al, “Recognition of Chylomicron Remnants and Beta-Migrating very-low Density Lipoproteins by the Remnant Receptor of Parenchymal Liver Cells is Distinct from the Liver Alpha 2-Macroglobulin Recognition Site,” Biochem J. 1991 No. 1; 279(Pt. 3): 863-70.
Benezra, M. et al, “A Synthetic Heparin-Mimicking Polyanionic Compound Binds to the LDL Receptor-related Protein and inhibits Vascular Smooth Muscle Cell Proliferation,” J. Cell Biochem 2001; 81(1): 114-27.
Hayashida et al, “Bovine Lactoferrin has a Nitric Oxide-dependent Hypotensive Effect in Rats,” Am J Physiol Regul Integr Comp Physiol. Feb. 2004; 286(2): R359-65.
Llirbat et al, “Normal and Inhibited Cholesterol Synthesis in the Cultured Rat Embryo,” Journal of Lipid Research vol. 38, pp. 22-34 (1997).

Affiliated with

Also associated with

Rating

Lactoferrin in the reduction of circulating cholesterol,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Lactoferrin in the reduction of circulating cholesterol,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lactoferrin in the reduction of circulating cholesterol,... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3617823